Login to Your Account

Gaining on the Pain: Adventrx To Start Phase III in Sickle Cell

By Randy Osborne
Staff Writer

Friday, October 26, 2012

The hot-potato history of the drug candidate that carries the strongest hope for sickle-cell disease (SCD) patients goes back more than two decades, but investors hope the buck will stop with Adventrx Pharmaceuticals Inc. – and plenty of bucks lie ahead, should ANX-188 win at last in upcoming Phase III trials.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription